Patents by Inventor Roderick S. Davis

Roderick S. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS
    Publication number: 20230103791
    Abstract: The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X): wherein Y?, X?, B?, R1?, R2?, R3?, R5?, R6?, R7?, and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.
    Type: Application
    Filed: June 23, 2020
    Publication date: April 6, 2023
    Inventors: Roderick S. DAVIS, Mark ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, William H. MILLER, Joseph J. ROMANO, Mythily VIMAL, Maben YING, David G. WASHBURN
  • Nrf2 REGULATORS
    Publication number: 20230047296
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: February 16, 2023
    Inventors: Jeffrey K. KERNS, James Callahan, Hongxing Yan, Thomas Daniel Heightman, Charlotte Mary Griffiths-Jones, Alison Jo-Anne Woolford, Tindy Li, Ami Lakdawala Shah, Roderick S. Davis, David Norton, Jeffrey Charles Boehm, Paris L. Hamilton, Nicole Cathleen Goodwin, Yun Jin
  • BISARYL LACTAMS AS NRF2 ACTIVATORS
    Publication number: 20220002272
    Abstract: The present invention relates to bisaryl lactam compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: January 6, 2022
    Inventors: Jeffrey Charles BOEHM, Roderick S. DAVIS, Nicole Cathleen GOODWIN, Jeffrey K. KERNS, Tindy LI, Hongxing YAN
  • Bisaryl heterocycles as NRF2 activators
    Patent number: 11117905
    Abstract: The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 14, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: James Francis Callahan, Roderick S. Davis, Nicole Cathleen Goodwin, Jeffrey K. Kerns
  • Nrf2 regulators
    Patent number: 10604509
    Abstract: Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 31, 2020
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: Jeffrey K. Kerns, James Callahan, Thomas Daniel Heightman, Alison Jo-Anne Woolford, Ami Lakdawala Shah, Roderick S. Davis, David Norton, Jeffrey Charles Boehm, Nicole Cathleen Goodwin
  • Nrf2 REGULATORS
    Publication number: 20200079759
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 12, 2020
    Inventors: Jeffrey K. KERNS, James Callahan, Hongxing Yan, Thomas Daniel Heightman, Charlotte Mary Griffiths-Jones, Alison Jo-Anne Woolford, Tindy Li, Ami Lakdawala Shah, Roderick S. Davis, David Norton, Jeffrey Charles Boehm, Paris L. Hamilton, Nicole Cathleen Goodwin, Yun Jin
  • BISARYL HETEROCYCLES AS NRF2 ACTIVATORS
    Publication number: 20200062781
    Abstract: The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: February 27, 2020
    Inventors: James Francis CALLAHAN, Roderick S. DAVIS, Nicole Cathleen GOODWIN, Jeffrey K. KERNS
  • NRF2 Regulators
    Publication number: 20190002454
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Jeffrey Charles BOEHM, Thomas Glanmor DAVIES, Alison Jo-Anne WOOLFORD, Charlotte Mary GRIFFITHS-JONES, Hendrika Maria Gerarda WILLEMS, David NORTON, Gordon SAXTY, Thomas Daniel HEIGHTMAN, Tindy LI, Jeffrey K. KERNS, Roderick S. DAVIS, Hongxing YAN
  • Nrf2 REGULATORS
    Publication number: 20180179187
    Abstract: Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 28, 2018
    Inventors: Jeffrey K. KERNS, James CALLAHAN, Hongxing YAN, Thomas Daniel HEIGHTMAN, Charlotte Mary GRIFFITHS-JONES, Alison Jo-Anne WOOLFORD, Tindy LI, Ami Lakdawala SHAH, Roderick S. DAVIS, David NORTON, Jeffrey Charles BOEHM, Paris L. HAMILTON
  • NRF2 REGULATORS
    Publication number: 20160318917
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Inventors: Jeffrey Charles Boehm, Thomas Glanmor Davies, Alison Jo-anne Woolford, Charlotte Mary Griffiths-Jones, Hendrika Maria Gerarda Willems, David Norton, Gordon Saxity, Thomas Daniel Heightman, Tindy Li, Jeffrey K. Kerns, Roderick S. Davis, Hongxing Yan
  • VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
    Publication number: 20140121213
    Abstract: In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.
    Type: Application
    Filed: July 3, 2012
    Publication date: May 1, 2014
    Inventors: Jeffrey Charles Boehm, Roderick S. Davis, Jeffrey Kerns, Guoliang Lin, Robert D. Murdoch, Hong NIE
  • VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
    Publication number: 20130023541
    Abstract: The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.
    Type: Application
    Filed: January 13, 2011
    Publication date: January 24, 2013
    Inventors: Jeffrey Charles Boehm, Roderick S. Davis, Jeffrey K. Kerns, Guoliang Lin, Hong Nie
  • Substituted oxoazaheterocyclyl compounds
    Patent number: 7612075
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: November 3, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Michael R. Myers, Wan F. Lau, Aiwen Li, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • M3 Muscarinic Acetylcholine Receptor Antagonists
    Publication number: 20080275079
    Abstract: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
    Type: Application
    Filed: August 2, 2006
    Publication date: November 6, 2008
    Inventors: Jakob Busch-Petersen, Dramane Ibrahim Laine, Michael R. Palovich, Roderick S. Davis, Wei Fu, Haibo Xie
  • M3 Muscarinic Acetylcholine Receptor Antagonists
    Publication number: 20080234315
    Abstract: The present invention is directed to novel Muscarinic Acetylcholine receptor antagonists of Formula (I), pharmaceutical compositions and methods of using them. Compounds of Formula (I) are, inter alia, wherein: R1 and R2 are, independently, selected from the group consisting of 3-thienyl, pyridyl, benzyl, pyrimidyl, thiazolyl, isothiazolyl and C3-7cycloalkyl.
    Type: Application
    Filed: August 2, 2006
    Publication date: September 25, 2008
    Inventors: Jakob Busch-Petersen, Dramane Ibrahim Laine, Michael R. Palovich, Roderick S. Davis, Wei Fu, Haibo Xie
  • Substituted oxoazaheterocyclyl compounds
    Publication number: 20040102450
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
    Type: Application
    Filed: July 25, 2003
    Publication date: May 27, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Aiwen Li, Michael R. Myers, Wan F. Lau, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
    Patent number: 6034093
    Abstract: The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: March 7, 2000
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Daniel G. McGarry, Roderick S. Davis, Alfred P. Spada
  • Substituted sulfonic acid n-?(aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
    Patent number: 5731315
    Abstract: The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: March 24, 1998
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Daniel G. McGarry, Roderick S. Davis, Alfred P. Spada